NCT02407041View on ClinicalTrials.gov

An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Psoriasis
Interventions
DRUG

GR-MD-02

IV infusion

Trial Locations (1)

78234

Brooke Army Medical Ctr., San Antonio

Sponsors
All Listed Sponsors
lead

Galectin Therapeutics Inc.

INDUSTRY